Phacoemulsification in Acute Congestive Glaucoma

Glaucoma Clinical Trial

Official title:

Phacoemulsification in Acute Congestive Glaucoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05289453
• Other study ID #: soh-med-22-02-29
• Status: Recruiting
• Phase: N/A
• Start date: February 20, 2022
• Est. completion date: June 20, 2022

Study information

• Verified date: March 2022
• Source: Sohag University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Acute primary angle closure (APAC) is usually caused by an abrupt closure of the trabecular meshwork in the anterior chamber angle that leads to a sudden rise in intraocular pressure (IOP). APAC is a subgroup of angle closure disease characterised by a sudden onset of headache, blurred vision, seeing halos around lights, corneal oedema, mid-dilated pupil, eye pain and redness. Asian also has a much higher incident rate of APAC compare to the Caucasian population - with the crude incidence rate of 12.2 and 10.4 per 100,000 people per year in the above 30-year-old population of Singapore and Hong Kong, respectively . This is higher than the average incidence rate of 3.9-4.1 cases per 100,000 people per year in the European regions .

In APAC, both LPI and primary lens extraction by phacoemulsification and intraocular lens implant (phaco/IOL) were demonstrated to be effective to control IOP elevation. The latter has been shown to be the more effective treatment than LPI for IOP reduction at the early and mid-term IOP control. Together with the advancement of phaco/IOL technique, primary lens extraction is the more popular choice of treatment nowadays. However, operating on an eye with early aborted APAC is technically challenging and may increase the risk of complications because of the presence of corneal oedema, inflammation, shallow anterior chamber, floppy iris and unstable lens. Furthermore, "the best time window" for performing lens extraction after an APAC attack remains uncertain. The long-term results (e.g. more than 5 years) of early lens extraction compared to the conventional LPI are also unknown. In this study, we summarise the approach of treating APAC at the initial acute stage and review the studies that consider IOP control in the mid and long term. We would also touch on the role of goniosynechialysis, trabeculectomy and endoscopic cyclophotocoagulation in treating APAC, as well as considering the economic aspect of treatment.

Aim of the study: to evaluate the safety and efficacy of phacoemulsificatiojn in cases of acute congestive glaucoma

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: June 20, 2022
• Est. primary completion date: June 20, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• patients with acute congestive glaucoma

Exclusion Criteria:

• people under 18 years

Related Conditions & MeSH terms

• Glaucoma

Intervention

Procedure:
• lens extraction by phacoemulsification
lens extraction by phacoemulsification

Locations

Country	Name	City	State
Egypt	Hany Mahmoud	Sohag

Sponsors (1)

Lead Sponsor	Collaborator
Hany Mahmoud

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	iop control	iop will be assessed by applination tonometry and the values will be recorded, the success is defined by normal iop values during follow up period (3 months)	3 months follow-up